Whether anti-PD-1 therapy is beneficial for newly diagnosed GBM is currently being investigated in two randomized phase III clinical trials, CheckMate-498 and CheckMate-548 trials (NCT02617589 and NCT02667587), as well as the phase II PERGOLA trial (NCT03899857). This evidence concerns the gene PDCD1 and glioblastoma.